Skip to main content
. Author manuscript; available in PMC: 2016 Sep 15.
Published in final edited form as: J Neuroimmunol. 2015 Jul 6;286:16–24. doi: 10.1016/j.jneuroim.2015.07.001

Figure 4. Intravenous rimonabant does not modulate pulmonary LPS effects.

Figure 4

Following hemodynamic measurements, lungs isolated from rats exposed to systemic LPS (5mg/kg) for 30 minutes with or without intracerebroventricular or intravenous rimonabant pretreatment (500 ng in 0.5 μl saline + 2.5% DSMO), were separated into left and right halves. Right lungs were homogenized, and supernatants, 20 μg/lane, were Western blotted. The blot lane labels are: C=control, R=rimonabant, L=LPS, RL=ICV rimonabant pretreatment + LPS, IVRL=IV rimonabant pretreatment + LPS. A) Representative blots of IRAK1, IκBα, and β-actin and the Western blot band densities of IRAK1 and IκBα in relative density units (RDU) B) Representative blots of phospho-SFKTyr416, total Src, and β-actin and the Western blot RDU for phospho-SFKTyr416. C) Representative blots of total RAF1 and β-actin and the Western blot RDU for RAF1. Data are mean ± S.E.M. Significance was at P<0.05. * = significantly different from control. # = significantly different from the LPS-only group. $ = significantly different from the ICV rimonabant + LPS group.